News

ABSTRACTIntroductionLight chain (AL) amyloidosis and transthyretin amyloid cardiomyopathy (ATTR-CM) are the most common types of cardiac amyloidosis. Despite…

ABSTRACTBACKGROUND Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive, life-threatening disease. Sociodemographic factors may influence time to…

The future of ATTR managementAmyloid cardiomyopathy, particularly transthyretin (ATTR) amyloidosis, has undergone a profound therapeutic transformation over the…

Objective: To evaluate demographics, clinical presentation, diagnostic delay, treatment patterns, genotype-phenotype correlations, and outcomes in patients with…

AbstractBackgroundTransthyretin cardiac amyloidosis (ATTR-CM) is increasingly recognized in elderly patients with conduction disturbances and left ventricular…

Naples, Florida-based Attralus, Inc. announced receipt of US FDA orphan drug designation for zamubafusp alfa (AT-02) for the treatment of immunoglobulin light chain…

AbstractBackground: Volume assessment in cardiac amyloid light chain (AL) amyloidosis is challenging during high-dose chemotherapy and autologous stem cell…

Alnylam Pharmaceuticals ALNY is a commercial-stage company that currently markets four drugs. The company first received regulatory approval in 2018 for…

AbstractBackground: Cardiac transthyretin amyloidosis (ATTR-CM) is a progressive myocardial disease ultimately leading to heart failure. Standard diagnostic workup…

AbstractSystemic amyloid light-chain (AL) amyloidosis is a rare plasma cell disorder characterized by extracellular deposition of misfolded immunoglobulin light…